NSCLC: N3 Nodal Staging Linked to Higher VTE Risk

N3 nodal staging among patients with non-small cell lung cancer was associated with a significantly higher risk for developing VTE.
N3 nodal staging among patients with non-small cell lung cancer was associated with a significantly higher risk for developing VTE.

N3 nodal staging among patients with non-small cell lung cancer (NSCLC) was associated with a significantly higher risk for developing venous thromboembolism (VTE) compared with N0-N2 staging, a study published in the journal Lung Cancer has shown.1

Although patients with NSCLC are known to be at high risk for VTE, previous studies have not specifically evaluated locally advanced disease.

Therefore, researchers sought to retrospectively assess the VTE risk in a cohort of patients with locally advanced NSCLC who received therapy with definitive intent, including radiotherapy.

For the study, researchers analyzed data from 629 patients with stage 2 or 3 NSCLC who received care at a single institution between 2003 and 2012. All patients received treatment with curative intent, including radiation therapy.

Of those, 127 patients developed a VTE after a median follow-up of 31 months, with 80% of VTEs occurring in the first 12 months after treatment initiation.

Researchers estimated that the 1-year and 3-year overall cumulative incidence of VTE among patients with locally advanced NSCLC was 13.5% and 15.4%, respectively.

Results showed that N3 nodal disease and stage 3B disease were associated with higher VTE risk; however, after accounting for death and distant metastasis as competing risks, only N3 nodal disease continued to be associated with an increased risk for developing VTE (HR, 1.64; 95% CI: 1.06-2.54; P=.027).

REFERENCE

1. Li R, Hermann G, Baldini E, et al. Advanced nodal stage predicts venous thromboembolism in patients with locally advanced non-small cell lung cancer [published online ahead of print March 16, 2016]. Lung Cancer. doi:10.1016/j.lungcan.2016.03.004.

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs